Burney Company’s BridgeBio Pharma BBIO Stock Holding History

Burney Company’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.39M	Buy	+21,146	New	+$1.65M	0.04%	292

Other funds holding BBIO

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

CPBTD

Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Burney Company's BBIO Position: Q3 2026 in Review

Burney Company opened a new position in BridgeBio Pharma (BBIO) in Q3 2026: 21,146 shares worth $1.39M. The stake represents 0.04% of the portfolio and ranks #292 among its holdings.

38 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

Burney Company held 21,146 shares of BridgeBio Pharma worth $1.39M as of Q3 2026.
BridgeBio Pharma was a new Burney Company position in Q3 2026.
BridgeBio Pharma made up 0.04% of Burney Company's portfolio in Q3 2026, its #292 holding.
38 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on Burney Company's 13F filing for Q3 2026, filed 15 Oct 2026.